GO:0006958 complement activation, classical pathway: Immune Cascade, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006958 describes the classical pathway of complement activation, an antibody- and C1q-dependent cascade that directly kills microbes, clears immune complexes, and shapes immune responses.
• The classical pathway is initiated when C1q binds to antigen-bound IgM or IgG, activating C1r and C1s, which cleave C4 and C2 to form the C3 convertase C4b2a.
• Dysregulated classical pathway activation is pathogenic in membranous nephropathy, myasthenia gravis, ANCA-associated glomerulonephritis, and other immune-complex diseases.
• The classical pathway is also required for host defense against bacteria such as Enterococcus faecalis and Rickettsia species, so therapeutic inhibition must balance efficacy and infection risk.
• Key proteins include C1q, C1r, C1s, C4, C2, C3, C5, and regulators such as C1-inhibitor, factor H, and C4b-binding protein.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of classical pathway genes in disease and immunity.
Description
The classical pathway of complement activation (GO:0006958) is one of three routes that converge on the complement cascade, and it is uniquely triggered by antibodies bound to antigens. According to the Gene Ontology, this term covers any process involved in activating the steps of the classical pathway, which allows direct killing of microbes, disposal of immune complexes, and regulation of other immune processes. The pathway is initiated when C1q recognizes clustered Fc regions of IgM or IgG on a target surface, leading to activation of the C1r and C1s proteases and assembly of the C3 convertase C4b2a. Researchers study GO:0006958 because it sits at the intersection of humoral immunity, autoimmunity, and infection control. In membranous nephropathy, classical pathway activation drives pathogenic complement deposition and kidney injury. In myasthenia gravis with acetylcholine receptor antibodies, classical pathway activation correlates with disease activity. In myeloperoxidase-ANCA-associated glomerulonephritis, circulating immune complexes trigger classical pathway activation. At the same time, the pathway is essential for clearing pathogens such as Enterococcus faecalis and Rickettsia species, so its manipulation has therapeutic trade-offs. Understanding the molecular players and regulatory checkpoints of GO:0006958 is therefore central to translational immunology.
complement activation, classical pathway At A Glance
| GO ID | GO:0006958 |
|---|---|
| GO term | complement activation, classical pathway |
| Ontology | biological_process |
| Synonym | complement cascade, classical pathway |
| Major function | Antibody-dependent activation of complement leading to microbial killing, immune complex clearance, and immune regulation |
| Trigger | C1q binding to antigen-bound IgM or IgG |
| Key convertase | C4b2a (classical pathway C3 convertase) |
| Key regulators | C1-inhibitor, C4b-binding protein, factor H, decay-accelerating factor (CD55), CD59 |
| Effector outcomes | Opsonization, membrane attack complex formation, anaphylatoxin release, immune complex clearance |
What Is GO:0006958?
In plain terms, GO:0006958 is the antibody-triggered branch of the complement system. It includes the molecular events that begin when C1q binds immune complexes and proceed through protease activation, convertase assembly, and downstream effector functions such as opsonization, lysis, and inflammation. The QuickGO definition emphasizes that this process enables direct killing of microbes, disposal of immune complexes, and regulation of other immune processes.
Why Is complement activation, classical pathway Important in Cell Biology?
GO:0006958 is important because it is a central effector arm of antibody-mediated immunity and a major driver of tissue injury in autoimmune and immune-complex diseases. It is also a validated therapeutic target: blocking C2 with ARGX-117 inhibits classical pathway activation and has been explored clinically. At the same time, the pathway is required for defense against certain bacterial pathogens, so inhibition can impair bacterial clearance. This dual role makes precise mechanistic understanding essential for drug development and biomarker discovery.
• Drives pathogenic complement deposition in membranous nephropathy.
• Correlates with disease activity in myasthenia gravis with AChR antibodies.
• Is activated by circulating immune complexes in MPO-ANCA-associated glomerulonephritis.
• Can be regulated by cross-talk with the coagulation system via factor H and fibrin clots.
• Is a target for therapeutic inhibition, e.g., anti-C2 antibody ARGX-117.
• Is required for clearance of Enterococcus faecalis in infection models.
• Contributes to control of Rickettsia infection together with IgM.
• Defects in complement components cause immunodeficiency syndromes.
• Provides biomarkers for immune complex diseases and transplant rejection.
• Offers CRISPR-tractable targets for causal validation in disease models.
What Happens During complement activation, classical pathway?
Initiation by C1q recognition of immune complexes
In simple terms: The pathway starts when C1q grabs onto antibodies that are stuck to a target.
The classical pathway is initiated when C1q, a hexameric recognition protein, binds to the Fc regions of antigen-bound IgM or IgG on a surface. This binding clusters C1q and activates the associated C1r protease, which then activates C1s. In membranous nephropathy, this initiation step is pathogenic because autoantibodies deposit on the glomerular basement membrane and recruit C1q. In myasthenia gravis, AChR antibodies trigger classical pathway activation at the neuromuscular junction.
C1s-mediated cleavage of C4 and C2
In simple terms: Activated C1s cuts two proteins, C4 and C2, to build the next enzyme complex.
Activated C1s cleaves C4 into C4a and C4b, exposing a thioester that covalently attaches C4b to the target surface. C1s also cleaves C2, and the resulting C2a fragment binds C4b to form the C3 convertase C4b2a. This step is a key amplification point and is targeted by therapeutic inhibitors such as ARGX-117, an antibody against C2.
C3 convertase activity and amplification
In simple terms: The C4b2a enzyme chops C3 into pieces that coat microbes and recruit more immune cells.
The classical pathway C3 convertase, C4b2a, cleaves C3 into C3a and C3b. C3b covalently deposits on the target, promoting opsonization and forming the C5 convertase (C4b2a3b) that initiates the terminal pathway. This amplification loop is central to the pathway's effector functions and is dysregulated in immune-complex diseases.
Terminal pathway and membrane attack complex
In simple terms: The final steps punch holes in target cells and release signals that cause inflammation.
C5 convertase cleaves C5 into C5a and C5b. C5b nucleates assembly of C6, C7, C8, and multiple C9 molecules into the membrane attack complex (MAC), which lyses susceptible targets. C3a and C5a are anaphylatoxins that recruit and activate immune cells. In MPO-ANCA-associated glomerulonephritis, immune complexes drive classical pathway activation and downstream injury.
Regulation by complement inhibitors
In simple terms: Brakes on the pathway prevent it from attacking healthy tissues.
C1-inhibitor blocks C1r and C1s activity, while C4b-binding protein and factor I degrade C4b, and decay-accelerating factor (CD55) and CD59 limit convertase and MAC formation. Factor H also regulates classical pathway activation in the context of fibrin clots, illustrating cross-talk with coagulation. Loss of these checkpoints contributes to autoimmune pathology.
Key Genes Involved in GO:0006958 complement activation, classical pathway
The classical pathway involves a defined set of complement proteins, proteases, and regulators that can be targeted with CRISPR models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| C1QA | C1q subunit; recognizes antibody Fc | Initiation of classical pathway; autoimmune target |
| C1QB | C1q subunit; recognizes antibody Fc | Initiation of classical pathway; autoimmune target |
| C1QC | C1q subunit; recognizes antibody Fc | Initiation of classical pathway; autoimmune target |
| C1R | C1r protease; activates C1s | Proteolytic activation step; drug target |
| C1S | C1s protease; cleaves C4 and C2 | Central enzymatic step; inhibitor target |
| C4A | C4 isoform; forms C4b | Convertase assembly; immune complex clearance |
| C4B | C4 isoform; forms C4b | Convertase assembly; immune complex clearance |
| C2 | Forms C2a; part of C3 convertase | Therapeutic target (ARGX-117) |
| C3 | Central complement protein; C3b opsonin | Amplification and effector functions |
| C5 | Forms C5b; initiates MAC | Terminal pathway; anti-C5 therapies |
| C6 | MAC component | Membrane attack complex assembly |
| C7 | MAC component | Membrane attack complex assembly |
| C8A | MAC component | Membrane attack complex assembly |
| C9 | MAC component | Pore formation and lysis |
| SERPING1 | C1-inhibitor; blocks C1r/C1s | Regulation; hereditary angioedema |
| C4BPA | C4b-binding protein alpha | Regulation of C4b; cofactor for factor I |
| CFH | Factor H; regulates C3 convertase | Cross-talk with coagulation |
| CD55 | Decay-accelerating factor | Protects host cells from complement |
How Is complement activation, classical pathway Regulated?
The classical pathway is tightly regulated at multiple nodes. C1-inhibitor (SERPING1) covalently inhibits C1r and C1s, preventing spontaneous activation. C4b-binding protein and factor I degrade C4b, while decay-accelerating factor (CD55) dissociates the C3 convertase and CD59 blocks MAC assembly. Factor H also regulates classical pathway activation on fibrin clots, linking complement to coagulation. Therapeutic regulation is achievable with anti-C2 antibodies such as ARGX-117, which block the pathway at the convertase assembly step.
complement activation, classical pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| C1Q | Membranous nephropathy; autoimmunity | KO mouse; patient-derived podocytes |
| C2 | Myasthenia gravis; complement inhibition | C2 KO; ARGX-117 treatment model |
| C3 | ANCA-associated glomerulonephritis | C3 KO; immune complex injection model |
| C4 | Immune complex clearance; infection | C4 KO; bacterial challenge |
| CFH | Coagulation-complement cross-talk | CFH KO; fibrin clot model |
Membranous nephropathy
In membranous nephropathy, the classical pathway triggers pathogenic complement activation, leading to glomerular injury and proteinuria. Autoantibodies against podocyte antigens recruit C1q and initiate the cascade. This makes classical pathway components attractive biomarkers and therapeutic targets.
Myasthenia gravis
In myasthenia gravis with acetylcholine receptor antibodies, classical complement pathway activation occurs at the neuromuscular junction and correlates with disease severity. Inhibiting this pathway is a therapeutic strategy.
ANCA-associated glomerulonephritis
Circulating immune complexes activate the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis, contributing to renal inflammation and injury. This highlights the role of immune complexes in driving complement-mediated damage.
Infection and immunodeficiency
The classical pathway is required for clearance of Enterococcus faecalis and Rickettsia species, and deficiencies in complement components cause immunodeficiency syndromes. Therapeutic inhibition must therefore consider infection risk.
From complement activation, classical pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does C1q initiate classical pathway in membranous nephropathy? | C1q KO mouse or podocyte-specific KO |
| Can C2 inhibition reduce myasthenia gravis severity? | C2 KO or anti-C2 antibody treatment |
| How do immune complexes activate classical pathway in ANCA vasculitis? | C3 KO or C4 KO mouse with MPO-ANCA |
| Does factor H regulate classical pathway on fibrin clots? | CFH point-mutation knock-in |
| Is classical pathway required for Enterococcus faecalis clearance? | C3 KO or C4 KO infection model |
| Does IgM control Rickettsia via classical pathway? | C1q KO or IgM KO mouse |
How to Study the complement activation, classical pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CH50 hemolytic assay | Functional classical pathway activity | Diagnosis of complement deficiencies |
| C3a/C5a ELISA | Anaphylatoxin release | Monitoring activation in disease |
| Immunofluorescence | Tissue deposition of C1q, C3c, C4d, C5b-9 | Kidney and muscle biopsies |
| Western blot | Protein levels of complement components | Cell and tissue lysates |
| Mass spectrometry | Complement protein complexes | Serum and immune complex analysis |
| CRISPR knockout screen | Genes regulating complement activation | Functional genomics |
| Flow cytometry | C3b/C4b deposition on cells | Opsonization assays |
| qPCR | mRNA expression of complement genes | Inflammation studies |
Complement activation assays
CH50 and AH50 hemolytic assays measure functional classical pathway activity. ELISA-based assays detect C3a, C5a, and sC5b-9 as activation markers.
Immunofluorescence and imaging
Immunofluorescence staining for C1q, C3c, C4d, and C5b-9 on tissue biopsies reveals classical pathway deposition in diseases such as membranous nephropathy and myasthenia gravis.
Proteomics and immunoprecipitation
Mass spectrometry-based proteomics and immunoprecipitation can identify complement components and immune complexes in patient sera, as shown in MPO-ANCA-associated glomerulonephritis.
CRISPR screening and functional genomics
Pooled CRISPR knockout screens can identify genes that regulate classical pathway activation and complement-mediated cytotoxicity, enabling unbiased discovery of pathway modulators.
How CRISPR Can Be Used to Study GO:0006958 complement activation, classical pathway
Knockout
CRISPR knockout of C1QA, C1R, C1S, C2, C3, or C4 abolishes classical pathway activation and can be used to test causality in disease models such as membranous nephropathy and infection.
Point Mutation
Point mutations in C2 or CFH can mimic patient variants that alter classical pathway regulation, enabling structure-function studies and drug response testing.
Knock-in
Knock-in of tagged C3 or C4 allows tracking of complement deposition and convertase assembly in live cells and tissues.
Overexpression
Overexpression of C1q or C2 can amplify classical pathway activation in cell models to study downstream injury and screen inhibitors.
How EDITGENE Supports complement activation, classical pathway Research
Researchers studying complement activation, classical pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, immune complex clearance, or disease pathology. EDITGENE provides CRISPR-based cell models and screening services to accelerate this causal validation.
Contact EDITGENE today to design your custom CRISPR model for complement activation, classical pathway research.
Frequently Asked Questions About complement activation, classical pathway
What is complement activation, classical pathway?
It is the antibody-triggered branch of the complement system, defined by GO:0006958, that leads to microbial killing, immune complex clearance, and immune regulation.
What genes are involved in complement activation, classical pathway?
Key genes include C1QA, C1QB, C1QC, C1R, C1S, C4A, C4B, C2, C3, C5, C6, C7, C8A, C9, SERPING1, C4BPA, CFH, and CD55.
How is the classical pathway initiated?
It begins when C1q binds to antigen-bound IgM or IgG, activating C1r and C1s proteases.
What is the C3 convertase of the classical pathway?
The classical pathway C3 convertase is C4b2a, which cleaves C3 into C3a and C3b.
Which diseases involve classical pathway activation?
Membranous nephropathy, myasthenia gravis, ANCA-associated glomerulonephritis, and complement deficiencies.
Can the classical pathway be inhibited therapeutically?
Yes, anti-C2 antibodies such as ARGX-117 block classical pathway activation and are being developed for complement-mediated diseases.
Does the classical pathway help fight infections?
Yes, it is required for clearance of Enterococcus faecalis and contributes to control of Rickettsia infection.
How is the classical pathway regulated?
By C1-inhibitor, C4b-binding protein, factor I, factor H, CD55, and CD59.
What methods are used to study classical pathway activation?
CH50 assays, ELISA for C3a/C5a, immunofluorescence, proteomics, and CRISPR screens.
What CRISPR models are available for classical pathway research?
Knockout, point-mutation, knock-in, and overexpression models for C1q, C2, C3, C4, and regulators.
Conclusion
GO:0006958 complement activation, classical pathway is a fundamental biological process that bridges antibody recognition to complement effector functions. Its dysregulation drives autoimmune and immune-complex diseases, while its normal function is essential for host defense. CRISPR-based models and functional screens are powerful tools to dissect the pathway and identify therapeutic targets. EDITGENE offers comprehensive services to support this research.
References
- 1. Seifert L et al.. 2023. The classical pathway triggers pathogenic complement activation in membranous nephropathy.. Nat Commun 14(1):473 PMID: 36709213
- 2. McMurray JC et al.. 2024. Immunodeficiency: Complement disorders.. Allergy Asthma Proc 45(5):305-309 PMID: 39294906
- 3. Ozawa Y et al.. 2023. Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies.. Muscle Nerve 68(5):798-804 PMID: 37705312
- 4. Van de Walle I et al.. 2021. ARGX-117, a therapeutic complement inhibiting antibody targeting C2.. J Allergy Clin Immunol 147(4):1420-1429.e7 PMID: 32926878
- 5. Kojima T et al.. 2022. Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis.. Ren Fail 44(1):714-723 PMID: 35491890
- 6. Kang YH et al.. 2024. Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots.. Front Immunol 15:1368852 PMID: 38933264
- 7. Shehab El-Din EMR et al.. 2021. Inhibition of the Classical Pathway of Complement Activation Impairs Bacterial Clearance during Enterococcus faecalis Infection.. Infect Immun 89(5) PMID: 33593889
- 8. Dahmani M et al.. 2021. Contribution of classical complement activation and IgM to the control of Rickettsia infection.. Mol Microbiol 116(6):1476-1488 PMID: 34725868
